Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349258 · ClinicalTrials.gov registry record · Phase 4
The Use of GnRH Agonist Trigger in the Prevention of OHSS
A Phase 4 study, sponsored by University of Connecticut.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT00349258 is a Phase 4 study that has completed, run by University of Connecticut. The registered enrollment target is 66 participants.
The verdict
NCT00349258, a Phase 4 study, has completed, sponsored by University of Connecticut.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
To compare the incidence of ovarian hyperstimulation syndrome (OHSS) and implantation rate between high responder patients using Gonadotropin releasing GnRH) agonist or human chorionic gonadotropin (hCG) to trigger final oocyte maturation.
Interventions
- DRUG Leuprolide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349258
The ClinicalTrials.gov registry entry for NCT00349258 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Connecticut, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leuprolide acetate is the first listed.
NCT00349258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349258 about?
NCT00349258 is a clinical study titled "The Use of GnRH Agonist Trigger in the Prevention of OHSS". To compare the incidence of ovarian hyperstimulation syndrome (OHSS) and implantation rate between high responder patients using Gonadotropin releasing GnRH) agonist or human chorionic gonadotropin (hCG) to trigger final oocyte maturation.
What is the current status of trial NCT00349258?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2004-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00349258?
The interventions under investigation include: Leuprolide acetate (DRUG).
Who is sponsoring clinical trial NCT00349258?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.